In addition, difficulties are associated with the characteristics of AD and patience treatment compliance, as well as the fact that GAL is not able to cross the blood–brain-barrier (BBB) efficiently when administrated peripherically (i.e., orally or parenterally), making its oral used unsuitable. The gene discussed is GAL; the disease is Alzheimer disease.